In this section
@article{Trotter:2002,
author = {Trotter, CL and Ramsay, ME and Kaczmarski, EB},
journal = {Commun Dis Public Health},
pages = {220--225},
title = {Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign.},
url = {https://www.ncbi.nlm.nih.gov/pubmed/12434692},
volume = {5},
year = {2002}
}
TY - JOUR
AB - The UK was the first country to introduce meningococcal serogroup C conjugate vaccination. The vaccine was incorporated into the routine infant immunisation schedule and was offered to all under 18 year olds in a catch-up campaign. The vaccine has been well accepted in infants receiving routine vaccination, with coverage around 89%. Coverage in older children targeted in the catch-up campaign was above 85% up to the age of 14, and was lowest (43%) in 15-17 year olds not in education. The winter of 2000-01 was the first meningococcal season following the offer of the vaccination to all children and adolescents. The incidence of serogroup C disease in the targeted age groups fell by 80%, and the number of deaths in laboratory confirmed cases in 0-19 year olds decreased from 78 to 8 between 1998-99 and 2000-01. The incidence of serogroup B disease in all age groups was slightly higher in 2000-01 than previous years, and there was an increase in the incidence of serogroup C disease in those aged over 20 during the study period, leading to the extension of the vaccination campaign to 20-24 year olds.
AU - Trotter,CL
AU - Ramsay,ME
AU - Kaczmarski,EB
EP - 225
PY - 2002///
SN - 1462-1843
SP - 220
TI - Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign.
T2 - Commun Dis Public Health
UR - https://www.ncbi.nlm.nih.gov/pubmed/12434692
VL - 5
ER -
For any enquiries related to the MRC Centre please contact:
Scientific Manager
Susannah Fisher
mrc.gida@imperial.ac.uk
External Relationships and Communications Manager
Dr Sabine van Elsland
s.van-elsland@imperial.ac.uk